Literature DB >> 15541211

A case for botulinum toxin-A in idiopathic bladder overactivity.

Christopher P Smith1, George T Somogyi, Michael B Chancellor, Rodney A Appell.   

Abstract

Botulinum toxin (BTX) has been shown to be an effective agent in suppressing detrusor overactivity due to neurogenic causes. Similar to results obtained with traditional agents to treat bladder overactivity (ie, antimuscarinic medications), the use of BTX has been extended to patients with idiopathic detrusor overactivity. This article briefly reviews the use of BTX to treat disorders of detrusor overactivity and, based on early clinical and laboratory results, establishes the case for its use as a therapeutic modality to treat idiopathic detrusor overactivity.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15541211     DOI： 10.1007/s11934-004-0066-y

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN： 1527-2737            Impact factor:   2.862


  30 in total

1.  Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.

Authors:  B Schurch; M Stöhrer; G Kramer; D M Schmid; G Gaul; D Hauri
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

2.  Frey syndrome: treatment with type A botulinum toxin.

Authors:  J J von Lindern; B Niederhagen; S Bergé; G Hägler; R H Reich
Journal:  Cancer       Date:  2000-10-15       Impact factor: 6.860

3.  Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study.

Authors:  D D Dykstra; A A Sidi
Journal:  Arch Phys Med Rehabil       Date:  1990-01       Impact factor: 3.966

4.  Treatment of overactive bladder with botulinum toxin type B: a pilot study.

Authors:  Dennis Dykstra; Al Enriquez; Michael Valley
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-11-25

5.  Acetylcholinesterase-positive afferent axons in mucosa of urinary bladder of adult cats: retrograde tracing and degeneration studies.

Authors:  Y Wakabayashi; Y Kojima; Y Makiura; T Tomoyoshi; T Maeda
Journal:  Histol Histopathol       Date:  1995-07       Impact factor: 2.303

6.  Subcutaneous administration of botulinum toxin A reduces formalin-induced pain.

Authors:  Minglei Cui; Sid Khanijou; John Rubino; Kei Roger Aoki
Journal:  Pain       Date:  2004-01       Impact factor: 6.961

7.  Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience.

Authors:  David E Rapp; Alvaro Lucioni; Erin E Katz; R Corey O'Connor; Glenn S Gerber; Gregory T Bales
Journal:  Urology       Date:  2004-06       Impact factor: 2.649

8.  Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder.

Authors:  H Schulte-Baukloh; Th Michael; B Stürzebecher; H H Knispel
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

Review 9.  Emerging role of botulinum toxin in the management of voiding dysfunction.

Authors:  Christopher P Smith; Michael B Chancellor
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

Review 10.  Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

Authors:  K-E Andersson; M Yoshida
Journal:  Eur Urol       Date:  2003-01       Impact factor: 20.096
View more
  1 in total

Review 1.  [Botulinum toxin for the treatment of neurogenic detrusor hyperactivity. Consensus paper on use for neurogenic bladder dysfunction].

Authors:  K-D Sievert; J Bremer; H Burgdörfer; B Domurath; C Hampel; J Kutzenberger; C Seif; M Stöhrer; B Wefer; J Pannek
Journal:  Urologe A       Date:  2007-03       Impact factor: 0.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.